NCT01677858: Phase 1/2: Weekly Carfilzomib + Dex for Progressive Multiple Myeloma (CHAMPION 1)

CHAMPION

Kd

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (CHAMPION 1)

The study had the following primary objectives:

• Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior therapies

• Phase 2: to estimate the overall response rate (ORR) for patients with relapsed or refractory multiple myeloma who received 1 to 3 prior therapies treated with carfilzomib and dexamethasone QW at the MTD established in phase 1.

Sponsor

Amgen

---

ClinicalTrials.gov Identifier: NCT01677858

Official Title: A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

First Posted: September 3, 2012

Click here for details on ClinicalTrials.gov

---

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

---

Blood; 2016 Jun

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Click here for details

---

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Florida

United States, Illinois

United States, Indiana

United States, Maryland

United States, New Jersey

United States, New Mexico

United States, New York

United States, Oregon

United States, Tennessee

United States, Texas

United States, Virginia

United States, Washington